Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 53 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: gadobutrol Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging

NCT00623467
View directory record Official record
Conditions
Central Nervous System Diseases
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 30, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

NCT01344447
View directory record Official record
Conditions
Carotid Stenosis
Interventions
Gadobutrol (Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Jacksonville, Florida • Savannah, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Sep 30, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)

NCT03986138
View directory record Official record
Conditions
Lesion in Body Region
Interventions
gadopiclenol, Gadobutrol 1 MMOLE/ML Intravenous Solution
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Farmington, Connecticut • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 30, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

NCT03996447
View directory record Official record
Conditions
CNS Lesion, Blood Brain Barrier Defect
Interventions
gadopiclenol, Gadobutrol 1Mmol/mL Solution for Injection Vial
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Panorama City, California • Farmington, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 30, 2026, 5:12 PM EDT
Completed Phase 3 Interventional

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

NCT05915702
View directory record Official record
Conditions
Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Indian Wells, California • Orange, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Sep 30, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging

NCT00709852
View directory record Official record
Conditions
Diagnostic Imaging, Central Nervous System Diseases
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875), Gadoteridol (ProHance)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Los Gatos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Sep 30, 2026, 5:12 PM EDT
Recruiting No phase listed Observational

Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

NCT03067467
View directory record Official record
Conditions
Brain Tumor Adult
Interventions
Hyperpolarized 13C-Pyruvate, Gadolinium
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 30, 2026, 5:12 PM EDT
Withdrawn Not applicable Interventional

MR Guided Focused Ultrasound vs Radiotherapy for Palliative Pain Tx in Bone Metastases

NCT05250687
View directory record Official record
Conditions
Bone Metastases
Interventions
MR- High intensity focused ultrasound, External beam radiotherapy
Procedure · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 30, 2026, 5:12 PM EDT
Completed Not applicable Interventional

Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions

NCT04132843
View directory record Official record
Conditions
Brain Neoplasm, Lymphoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Malignant Brain Neoplasm
Interventions
Gadobenate Dimeglumine, Gadobutrol, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Sep 30, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

NCT01890421
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Gadobutrol (Gadovist, Gadavist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Sep 30, 2026, 5:12 PM EDT
Terminated No phase listed Observational

Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients

NCT02095353
View directory record Official record
Conditions
Central Nervous System Neoplasms
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 30, 2026, 5:12 PM EDT
Completed No phase listed Observational

A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting

NCT05350189
View directory record Official record
Conditions
Contrast Enhancement in Magnetic Resonance Imaging
Interventions
Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
1,602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 30, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

Gadobutrol Enhanced MRA of the Renal Arteries

NCT01344460
View directory record Official record
Conditions
Renal Artery Obstruction
Interventions
Gadobutrol (Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Sep 30, 2026, 5:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

NCT03504956
View directory record Official record
Conditions
Coronary Atherosclerosis
Interventions
Cardiac MRI, Contrast, Beta blocker
Device · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Sep 30, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Results available

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

NCT00862459
View directory record Official record
Conditions
Brain Diseases, Spinal Cord Diseases
Interventions
Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), OptiMARK~0.1 mmol/kg BW
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
20
States / cities
Sacramento, California • San Diego, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Sep 30, 2026, 5:12 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Whole-Heart Myocardial Blood Flow Quantification Using MRI

NCT03064295
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Microvascular Disease
Interventions
Myocardial Perfusion Cardiac MRI., Contrast, Pharmacologic Stress Agent
Device · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 30, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

NCT01104584
View directory record Official record
Conditions
Breast Cancer
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Tucson, Arizona • Oakland, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2014 · Synced Sep 30, 2026, 5:12 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients

NCT07472491
View directory record Official record
Conditions
Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion
Interventions
Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL, MRI Scan, Gadobutrol
Drug · Diagnostic Test
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 30, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI

NCT03404648
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
C-11 choline PET tracer, Gadobutrol, PET/MR scanner
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Sep 30, 2026, 5:12 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain

NCT01613417
View directory record Official record
Conditions
Brain Disease
Interventions
gadoteridol, gadobutrol
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 30, 2026, 5:12 PM EDT
Active, not recruiting Not applicable Interventional

Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

NCT02156739
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver and Intrahepatic Bile Duct Disorder, Metastatic Malignant Neoplasm in the Liver, Primary Malignant Liver Neoplasm
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Gadobutrol, Gadoxetate Disodium
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 30, 2026, 5:12 PM EDT
Completed Phase 1 Interventional

MR Image Synthesis With Low Gadobutrol Dose and AI

NCT06224543
View directory record Official record
Conditions
Enhancing Brain Lesions
Interventions
SubtleGAD, Gadobutrol
Device · Drug
Lead sponsor
Subtle Medical
Industry
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Peoria, Illinois • Worcester, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Sep 30, 2026, 5:12 PM EDT
Recruiting Phase 4 Interventional

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

NCT04373564
View directory record Official record
Conditions
Motor Function, Cognitive Function, Contrast Media
Interventions
Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Gadobenate dimeglumine, Gadodiamide, Gadoterate meglumine, Gadobutrol, Gadoteridol
Procedure · Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
16
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 30, 2026, 5:12 PM EDT
Withdrawn Phase 4 Interventional

Predicting Stroke Risk in ICAD With Novel MRI

NCT05515874
View directory record Official record
Conditions
Intracranial Atherosclerosis
Interventions
Feraheme
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 30, 2026, 5:12 PM EDT